Study guide

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway

Key Takeaways Explain This Topic AI

Glucose and galactose are aldohexoses and fructose is a ketohexose; sucrose (glucose plus fructose) is a non-reducing sugar, while lactose and maltose are reducing sugars.

PFK-1 is the rate-limiting enzyme of glycolysis; fructose-2,6-bisphosphate (raised by insulin) is its strongest activator.

The PDH complex needs thiamine (TPP), lipoic acid, CoA (pantothenate), FAD (riboflavin) and NAD+ (niacin); arsenic blocks lipoic acid, and PDH deficiency causes lactic acidosis.

G6PD is the rate-limiting enzyme of the pentose phosphate pathway, which supplies NADPH for glutathione, fatty acid and steroid synthesis and the respiratory burst.

Hereditary fructose intolerance (aldolase B) causes hypoglycemia and vomiting after fruit or sucrose; classic galactosemia (GALT) causes jaundice, cataracts, liver failure and E. coli sepsis in newborns fed milk.

Last updated: October 2026

Why this area matters

The 2025 Biochemistry TOS lists for carbohydrates: "carbohydrate biochemistry (structure and functions, classifications, properties and reactions), digestion and metabolism, ketogenesis, lipidogenesis and disorders, diseases of hormonal metabolism". This section covers chemistry and the glucose-oxidation pathways. The next section covers storage, gluconeogenesis, lipogenesis, ketogenesis and hormonal control. G6PD deficiency and galactosemia are on the Philippine expanded newborn screening panel, so they appear in both Biochemistry and Pediatrics items.

Structure, classification and reactions

Class Examples Notes

Monosaccharides Glucose, galactose (aldohexoses); fructose (ketohexose); ribose, deoxyribose (pentoses) Glucose and galactose are epimers at C-4; glucose and mannose at C-2

Disaccharides Sucrose (glucose-fructose, alpha-1 to beta-2), lactose (galactose-glucose, beta-1,4), maltose (glucose-glucose, alpha-1,4) Sucrose is non-reducing because both anomeric carbons are in the bond; lactose and maltose are reducing

Polysaccharides Starch (amylose alpha-1,4; amylopectin with alpha-1,6 branches), glycogen (more highly branched), cellulose (beta-1,4; indigestible fiber) Humans lack enzymes for beta-1,4 glucose links, so cellulose is dietary fiber

Glycosaminoglycans Hyaluronic acid, chondroitin, heparan, dermatan and keratan sulfate Accumulate in mucopolysaccharidoses (Hurler, Hunter)

Key reactions:

Free aldehyde or ketone groups reduce Benedict's and Fehling's reagents. Urine reducing-substance tests detect glucose, galactose and fructose; dipstick glucose oxidase strips detect only glucose.

Glucose reacts non-enzymatically with proteins (glycation), forming HbA1c and advanced glycation end-products.

Aldose reductase reduces glucose to sorbitol , which causes osmotic damage in the lens, nerves and retina in diabetes.

Digestion and absorption

Salivary and pancreatic alpha-amylase split starch into maltose, maltotriose and alpha-limit dextrins.

Brush-border disaccharidases (lactase, sucrase-isomaltase, maltase) release monosaccharides.

SGLT1 absorbs glucose and galactose with sodium; GLUT5 absorbs fructose; GLUT2 releases all three into the portal blood.

Lactase non-persistence , common in Asians, causes bloating and osmotic diarrhea after milk. Undigested lactose is fermented to gas and acids (low stool pH, positive hydrogen breath test).

Glucose transporters:

GLUT1 : red cells and the blood-brain barrier.

GLUT2 : liver, beta cells, kidney and intestine (bidirectional, high Km).

GLUT3 : neurons.

GLUT4 : muscle and fat, insulin-dependent .

The Glycolytic Pathway: Key Regulatory Steps and Erythrocyte Shunt

Glycolysis is the ubiquitous cytosolic pathway that converts one molecule of glucose ( 6 C 6\text{C} 6 C ) into two molecules of pyruvate ( 3 C 3\text{C} 3 C ), generating a net yield of 2 ATP 2\text{ ATP} 2 ATP and 2 NADH 2\text{ NADH} 2 NADH . Glycolysis operates in two phases: the preparatory (energy investment) phase, consuming 2 ATP 2\text{ ATP} 2 ATP , and the payoff phase, generating 4 ATP 4\text{ ATP} 4 ATP and 2 NADH 2\text{ NADH} 2 NADH .

Hexokinase versus Glucokinase: Kinetic and Tissue Specialization

The initial irreversible step traps intracellular glucose by phosphorylation to glucose-6-phosphate (G6P), catalyzed by two distinct isozymes:

Biochemical Parameter Hexokinase (Types I–III) Glucokinase (Hexokinase Type IV)

Primary Tissue Distribution Most peripheral tissues (brain, muscle, kidney) Hepatocytes and pancreatic β \beta β -islet cells

Substrate Affinity ( K m K_m K m ​ ) Low K m K_m K m ​ ( < 0.1 mM <0.1\text{ mM} < 0.1 mM , high affinity for glucose) High K m K_m K m ​ ( ≈ 10 mM \approx 10\text{ mM} ≈ 10 mM , low affinity for glucose)

Maximal Velocity ( V m a x V_{max} V ma x ​ ) Low V m a x V_{max} V ma x ​ (saturates rapidly at baseline) High V m a x V_{max} V ma x ​ (high capacity for large postprandial glucose loads)

Feedback Inhibition Directly inhibited by its product, Glucose-6-Phosphate Not inhibited by G6P; inhibited by Fructose-6-P via regulatory protein (GKRP)

Hormonal Regulation Unaffected by insulin Strongly induced transcriptionally by insulin

Physiological Function Guarantees basal glucose phosphorylation during fasting Clears portal glucose surges after meals; acts as pancreatic glucose sensor

Clinical Correlation Normal in diabetes Heterozygous loss-of-function mutation causes MODY-2 (Maturity-Onset Diabetes of the Young Type 2)

Phosphofructokinase-1 (PFK-1): The Primary Rate-Limiting Pacemaker

The phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F-1,6-BP) by Phosphofructokinase-1 (PFK-1) represents the definitive commitment and rate-limiting step of glycolysis:

Fructose-6-Phosphate + ATP → PFK-1 Fructose-1,6-Bisphosphate + ADP \text{Fructose-6-Phosphate} + \text{ATP} \xrightarrow{\text{PFK-1}} \text{Fructose-1,6-Bisphosphate} + \text{ADP} Fructose-6-Phosphate + ATP PFK-1 ​ Fructose-1,6-Bisphosphate + ADP

PFK-1 is subject to complex allosteric regulation:

Allosteric Inhibitors: High intracellular ATP (reflecting abundant energy charge) and Citrate (signaling active downstream Krebs cycle activity).

Allosteric Activators: High AMP and Fructose-2,6-bisphosphate (F-2,6-BP) , the most potent physiological activator.

F-2,6-BP is synthesized and degraded by a single bifunctional tandem enzyme containing two distinct catalytic domains: PFK-2 (kinase domain) and Fructose-2,6-bisphosphatase-2 (FBPase-2) (phosphatase domain):

Fed State (Insulin Dominance): Insulin signaling stimulates protein phosphatase-1, which dephosphorylates the bifunctional enzyme. Dephosphorylation activates the PFK-2 domain and inactivates FBPase-2, driving the synthesis of F-2,6-BP. Elevated F-2,6-BP allosterically activates PFK-1, accelerating glycolysis.

Fasting State (Glucagon Dominance): Glucagon binds G-protein-coupled receptors, elevating cAMP and activating Protein Kinase A (PKA). PKA phosphorylates the bifunctional enzyme. Phosphorylation inactivates PFK-2 and activates FBPase-2, degrading F-2,6-BP. Reduced F-2,6-BP relieves PFK-1 activation and derepresses gluconeogenesis.

Pyruvate Kinase and the Rapoport-Luebering Shunt

The final irreversible glycolytic reaction is catalyzed by Pyruvate Kinase , which transfers a high-energy phosphate from phosphoenolpyruvate to ADP, producing pyruvate and ATP. Pyruvate kinase is stimulated feedforward by upstream fructose-1,6-bisphosphate and allosterically inhibited by ATP and alanine. In the liver, glucagon-stimulated PKA phosphorylates and inactivates pyruvate kinase during fasting.

In mature erythrocytes, which lack mitochondria, glycolysis is the sole source of ATP. Erythrocytes feature a specialized collateral pathway: the Rapoport-Luebering shunt . In this bypass, bisphosphoglycerate mutase converts 1,3-BPG into 2,3-bisphosphoglycerate (2,3-BPG) . 2,3-BPG binds selectively to the central cavity of deoxygenated hemoglobin tetramers, stabilizing the T (taut) conformation and shifting the oxygen-hemoglobin dissociation curve to the right, facilitating oxygen unloading to hypoxic peripheral tissues. Because this bypass circumvents phosphoglycerate kinase, no ATP is generated from that triose branch.

Pyruvate Fates and the Pyruvate Dehydrogenase Complex

Under anaerobic conditions, pyruvate is reduced to lactate by cytosolic lactate dehydrogenase (LDH) , oxidatively regenerating N A D + NAD^+ N A D + to allow glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to sustain glycolysis. In aerobic tissues, pyruvate enters the mitochondrial matrix via the mitochondrial pyruvate carrier (MPC) to undergo irreversible oxidative decarboxylation to acetyl-CoA, catalyzed by the multi-enzyme Pyruvate Dehydrogenase (PDH) Complex :

Pyruvate + NAD + + CoA-SH → PDH Complex Acetyl-CoA + NADH + CO 2 + H + \text{Pyruvate} + \text{NAD}^+ + \text{CoA-SH} \xrightarrow{\text{PDH Complex}} \text{Acetyl-CoA} + \text{NADH} + \text{CO}_2 + \text{H}^+ Pyruvate + NAD + + CoA-SH PDH Complex ​ Acetyl-CoA + NADH + CO 2 ​ + H +

The Five Essential Coenzymes of the PDH Complex

The PDH complex comprises three catalytic subunits requiring five specific coenzymes derived from dietary vitamins:

E 1 E_1 E 1 ​ (Pyruvate Dehydrogenase): Requires Thiamine Pyrophosphate (TPP) , derived from Vitamin B1 (Thiamine).

E 2 E_2 E 2 ​ (Dihydrolipoyl Transacetylase): Requires Lipoic Acid and Coenzyme A (CoA) , derived from Vitamin B5 (Pantothenic acid).

E 3 E_3 E 3 ​ (Dihydrolipoyl Dehydrogenase): Requires FAD , derived from Vitamin B2 (Riboflavin), and N A D + NAD^+ N A D + , derived from Vitamin B3 (Niacin).

Mnemonic: "The Tender Loving Care For Nancy" (Thiamine, Lipoic acid, CoA, FAD, N A D + NAD^+ N A D + ).

Toxicological and Clinical Correlations

Arsenic Poisoning: Arsenite binds covalently to the vicinal sulfhydryl groups of dihydrolipoic acid, arresting both the PDH complex and α \alpha α -ketoglutarate dehydrogenase. Patients present with acute vomiting, profuse "rice-water" watery diarrhea, garlic odor on breath, and QT prolongation, progressing to encephalopathy and death.

PDH Complex Deficiency: Most commonly an X-linked mutation in the E 1 E_1 E 1 ​ - α \alpha α subunit gene ( PDHA1 ). Pyruvate accumulates and is shunted to lactate (causing severe lactic acidosis) and alanine. Affected infants exhibit psychomotor retardation, microcephaly, and hypotonia. Management involves a strict ketogenic diet high in fats and low in carbohydrates, supplemented with purely ketogenic amino acids ( lysine and leucine ), which generate acetyl-CoA directly without requiring the PDH complex.

The Pentose Phosphate Pathway and G6PD Deficiency

The Pentose Phosphate Pathway (Hexose Monophosphate Shunt) is a cytosolic collateral pathway of glucose oxidation that produces NADPH and Ribose-5-phosphate (for nucleotide synthesis) without consuming or generating ATP. The irreversible, rate-limiting oxidative step is catalyzed by Glucose-6-Phosphate Dehydrogenase (G6PD) :

Glucose-6-Phosphate + 2 NADP + + H 2 O → G6PD Ribulose-5-P + 2 NADPH + 2 H + + CO 2 \text{Glucose-6-Phosphate} + 2\text{ NADP}^+ + \text{H}_2\text{O} \xrightarrow{\text{G6PD}} \text{Ribulose-5-P} + 2\text{ NADPH} + 2\text{ H}^+ + \text{CO}_2 Glucose-6-Phosphate + 2 NADP + + H 2 ​ O G6PD ​ Ribulose-5-P + 2 NADPH + 2 H + + CO 2 ​

Physiological Roles of NADPH

Reductive Biosynthesis: Fatty acid, cholesterol, and steroid hormone synthesis.

Respiratory Burst: Substrate for phagocyte NADPH oxidase to generate superoxide ( O 2 ∙ − O_2^{\bullet-} O 2 ∙− ​ ).

Maintenance of Reduced Glutathione: Erythrocytes depend on NADPH to reduce oxidized glutathione (GSSG) back to reduced glutathione (GSH) via glutathione reductase. GSH detoxifies hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 ​ O 2 ​ ) and reactive oxygen species via glutathione peroxidase.

G6PD Deficiency (Favism / Drug-Induced Hemolysis)

Genetics: X-linked recessive disorder; most prevalent red cell enzymopathy worldwide (common in Mediterranean, African, and Southeast Asian/Filipino populations).

Pathophysiology: In erythrocytes (which lack mitochondria and alternative NADPH sources), G6PD deficiency impairs GSH regeneration. Oxidative stress leads to cross-linking of hemoglobin sulfhydryl groups, precipitating insoluble aggregates known as Heinz bodies .

Morphology: Splenic macrophages remove Heinz bodies, generating characteristic bite cells (degmacytes).

Triggers: Ingestion of fava beans ( Vicia faba ); infections; oxidizing medications including the antimalarials primaquine and tafenoquine, sulfonamides (sulfamethoxazole), dapsone, nitrofurantoin, and rasburicase.

Fructose and galactose disorders

  • Disorder Deficient enzyme Inheritance Key features
  • Essential fructosuria Fructokinase AR Benign; fructose appears in urine as a reducing sugar

Hereditary fructose intolerance Aldolase B AR Fructose-1-phosphate traps phosphate, so glycogenolysis and gluconeogenesis stop. Hypoglycemia, vomiting, jaundice and liver failure after eating fruit, juice, honey or sucrose , usually at weaning; children develop an aversion to sweets. Treat by removing fructose and sucrose

Classic galactosemia Galactose-1-phosphate uridyltransferase (GALT) AR Starts within days of milk feeding: vomiting, jaundice, hepatomegaly, cataracts (galactitol), intellectual disability, E. coli sepsis . Stop all lactose (use soy formula)

Galactokinase deficiency Galactokinase AR Milder; cataracts only (galactitol)

Lactic acidosis in a child may come from PDH deficiency, pyruvate carboxylase deficiency, mitochondrial disease or glycogen storage disease type I. A high lactate-to-pyruvate ratio points to a respiratory chain defect; a normal ratio points to a PDH defect.